ABOS
Acumen Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$181.29M
P/E Ratio
—
EPS
$-1.85
Beta
0.32
52W High
$3.60
52W Low
$0.99
50-Day MA
$2.59
200-Day MA
$2.14
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
Fundamentals
| Revenue (TTM) | 329,000 |
| Gross Profit (TTM) | $-104.89M |
| EBITDA | $-114.56M |
| Operating Margin | 0.00% |
| Return on Equity | -93.20% |
| Return on Assets | -42.40% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $1.21 |
| Price-to-Book | 2.07 |
| Price-to-Sales (TTM) | 538.78 |
| EV/Revenue | 24.48 |
| EV/EBITDA | -0.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.23M |
| Float | $37.01M |
| % Insiders | 6.67% |
| % Institutions | 63.99% |
Historical Volatility
HV 10-Day
68.91%
HV 20-Day
58.83%
HV 30-Day
58.77%
HV 60-Day
70.59%
HV Rank
2.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.40 target)
6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026